JP2023542528A5 - - Google Patents

Info

Publication number
JP2023542528A5
JP2023542528A5 JP2023518781A JP2023518781A JP2023542528A5 JP 2023542528 A5 JP2023542528 A5 JP 2023542528A5 JP 2023518781 A JP2023518781 A JP 2023518781A JP 2023518781 A JP2023518781 A JP 2023518781A JP 2023542528 A5 JP2023542528 A5 JP 2023542528A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
binding protein
polynucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542528A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051832 external-priority patent/WO2022066965A2/en
Publication of JP2023542528A publication Critical patent/JP2023542528A/ja
Publication of JP2023542528A5 publication Critical patent/JP2023542528A5/ja
Pending legal-status Critical Current

Links

JP2023518781A 2020-09-24 2021-09-23 Sox2抗原を標的とする免疫療法 Pending JP2023542528A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063083069P 2020-09-24 2020-09-24
US63/083,069 2020-09-24
PCT/US2021/051832 WO2022066965A2 (en) 2020-09-24 2021-09-23 Immunotherapy targeting sox2 antigens

Publications (2)

Publication Number Publication Date
JP2023542528A JP2023542528A (ja) 2023-10-10
JP2023542528A5 true JP2023542528A5 (cg-RX-API-DMAC7.html) 2024-10-02

Family

ID=78414071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518781A Pending JP2023542528A (ja) 2020-09-24 2021-09-23 Sox2抗原を標的とする免疫療法

Country Status (5)

Country Link
US (1) US20250018036A1 (cg-RX-API-DMAC7.html)
EP (1) EP4217387A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023542528A (cg-RX-API-DMAC7.html)
CN (1) CN116724053A (cg-RX-API-DMAC7.html)
WO (1) WO2022066965A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120302989A (zh) * 2022-10-05 2025-07-11 帝斯肯医疗公司 Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
WO2024148212A2 (en) * 2023-01-06 2024-07-11 The Trustees Of The University Of Pennsylvania T cell receptors directed to sox2 protein
CN122206692A (zh) * 2023-11-15 2026-06-12 格纳西尼有限公司 Skp2片段、其变体及其用途
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
KR20110134482A (ko) * 2009-03-19 2011-12-14 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 Sox2 유래의 hla-a24결합성 암 항원 펩티드
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
KR102397771B1 (ko) 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
PL3765615T3 (pl) 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna

Similar Documents

Publication Publication Date Title
CN112300269B (zh) Kras突变特异性t细胞受体筛选及抗肿瘤用途
Kershaw et al. Gene-engineered T cells for cancer therapy
JP2023145589A (ja) 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強
CA2974998C (en) Chimeric antigen receptors
JP2021168667A (ja) 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
WO2020044239A1 (en) A method to specifically stimulate survival and expansion of genetically-modified immune cells
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
CN110087672A (zh) 免疫调节多肽及相关组合物和方法
US20250073266A1 (en) Dosing regimens for cancer immunotherapy
JP2022527267A5 (cg-RX-API-DMAC7.html)
JP2022523971A5 (cg-RX-API-DMAC7.html)
CN114555815B (zh) T细胞受体及其使用方法
JP2022524994A5 (cg-RX-API-DMAC7.html)
JP2022525925A5 (cg-RX-API-DMAC7.html)
JP2022523553A5 (cg-RX-API-DMAC7.html)
JP2022524992A5 (cg-RX-API-DMAC7.html)
CN114502577A (zh) 结合病毒抗原的nk接合器化合物和使用方法
JP2022543059A5 (cg-RX-API-DMAC7.html)
CN114450414B (zh) T细胞受体及其使用方法
CA3118211A1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN114364806A (zh) T细胞受体及其使用方法
JP2022543060A5 (cg-RX-API-DMAC7.html)
JP7314161B2 (ja) ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法
JP2023526416A5 (cg-RX-API-DMAC7.html)
JP2021520813A5 (cg-RX-API-DMAC7.html)